# Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

> **NCT00110123** · PHASE3 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 171 (actual)

## Conditions studied

- Intraocular Melanoma
- Metastatic Cancer

## Interventions

- **DRUG:** fotemustine
- **DRUG:** isolated perfusion

## Key facts

- **NCT ID:** NCT00110123
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2011-06
- **Final completion:** —
- **Target enrollment:** 171 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110123, "Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00110123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*